Showing 1661-1670 of 2054 results for "".
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to
- Korean Ophthalmologist Oh Jungwoo Performs “25 Sec LASEK” in Public for the First Timehttps://modernod.com/news/korean-ophthalmologist-oh-jungwoo-performs-25-sec-lasek-in-public-for-the-first-time/2477147/Dr. Oh Jungwoo from Eos Eye Center in Gangnam-gu, Korea, revealed a “25 sec LASEK” surgery publicly by video. This is the first time the operation has been released to the public and it shows Dr. Oh’s surgery on a patient’s left eye with minimal corneal damage in 25 second
- Alcon Announces Timothy Stonesifer as Chief Financial Officerhttps://modernod.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/Alcon announced that Timothy C. Stonesifer will join the company as its new Senior Vice President and Chief Financial Officer, in conjunction with the company’s April 9 spinoff from Novartis. He will report directly to David Endicott, Alcon’s Chief Executive Officer, and bec
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- Acuvue Oasys with Transitions Light Intelligent Technology Named Among TIME’s ‘Best Inventions of 2018’https://modernod.com/news/acuvue-oasys-with-transitions-light-intelligent-technology-named-among-times-best-inventions-of-2018/2479661/TIME has selected Acuvue Oasys with Transitions Light Intelligent Technology as one of the ‘Best Inventions of 2018,’ in its annual round-up spotlighting groundbreaking innovations worldwide. The development of Acuvue Oasys with Transitions has created and defined an entirely new cate
- Swiss Advanced Vision Launches Active IOL Concept with Real-Time Autofocushttps://modernod.com/news/swiss-advanced-vision-launches-active-iol-concept-with-real-time-autofocus/2480257/Swiss Advanced Vision (SAV-IOL) has announced the launch of Project R-TASC (Real-Time Autofocus Servo Control), an active lens with real-time autofocus and wireless connectivity. Current lenses are fixed and suffer from optical compromises, such as light distribution, resolution, and visua
- Outdoor Time Linked to Lower Myopia Risk in Children in China, Large Study Findshttps://modernod.com/news/outdoor-time-linked-to-lower-myopia-risk-in-children-in-china-large-study-finds/2486596/Key Takeaways
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During